In recent years, monoclonal antibodies (mAbs) that target the PD-1/PD-L1 axis, such as pembrolizumab, nivolumab, avelumab, and atezolizumab, have been used in patient populations suffering from advanced-stage BC. This evidence concerns the gene CD274 and breast cancer.